Genyous Biomed

About MFMT Drug Development

Systems Biology — The study of biological systems taking into account the interactions of the key elements such as DNA, RNA, proteins, and cells with respect to one another within the cell, its micro environment, and the host.

Genyous’ Multifunctional Multitargeted (MFMT™) drug development platform (patent pending) is based on systems biology considerations that recognize the complex nature of chronic diseases and addresses the crosstalk between cells, their microenvironment (stroma) and the immune response system. MFMT™ drug design also minimizes disruption of homeostasis, thus reducing risk of toxicity and development of drug resistance. Genyous' multivalent drugs are designed to address the heterogeneous nature of chronic diseases by possessing multiple therapeutic functions and acting on multiple biological targets.

By applying modern biological assays (including genomics and proteomics) and proprietary processing methodologies optimized for classes of chemotypes possessing desired therapeutic effects, Genyous was able to screen natural sources and to subsequently formulate based on the discovery of synergistic therapeutic activity (patented). Genyous’ drug candidates are formulated with well-tolerated doses of actives derived from natural sources that have a long history of safe consumption and which are orally bioavailable.


The Company’s lead multivalent cancer drug candidate is Aneustat™ .

Aneustat™ Summary:

Aneustat Multifunctional Activity


Aneustat Multitargeted Activity Signaling Pathways: Lung Cancer

In pre-clinical in vivo studies conducted by the BC Cancer Agency, Aneustat™ demonstrated anti-cancer activity comparable to combination chemotherapy, but without any side effects.

Aneustat In Vivo Activity: Lung Cancer

Aneustat Multitargeted Activity Signaling Pathways: Prostate Cancer

Aneustat In Vivo Activity: Prostate Cancer

Combination drug therapy is the standard of care for many cancers. However, the utilization of more diverse combinations is often constrained by cumulative toxicities. Genyous' multivalent drugs are formulated to overcome these barriers and thus hold the potential to enhance the standard of care as well as to create an environment in which newer targeted therapies may be more effective. Based on pre-clinical studies, Aneustat has demonstrated synergy and complementary bioactivity with many currently marketed drugs, suggesting that Aneustat may be the ideal drug to use in combination with the current standard of care to improve outcomes while reducing toxicity burden.